Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs LY 3298176 (Primary) ; LY 3298176 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.
- 26 Dec 2017 New trial record